首页> 外国专利> Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer

Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer

机译:癌细胞中端粒长度的药理学调节可预防和治疗癌症

摘要

Acyclic nucleoside analogs such as acyclovir, ganciclovir, penciclovir and the corresponding pro-drugs, i.e., valacyclovir, valganciclovir and famciclovir, respectively have been identified as inhibitors or antagonists of both telomerase (encoded by TERT) and reverse transcriptase encoded by L-1 (LINE-1) RT, and as useful for treating or preventing cancers induced or mediated by the two enzymes. Method of treating or preventing such cancers in patients involves administration of a therapeutically effective amount of a composition having an inhibitor or antagonist of the reverse transcriptases in cells of the patients. The inhibitor or antagonist blocks lengthening of telomeres in telomerase positive and telomerase negative cells. Methods and kits for detecting pathologically proliferating cells expressing TERT and L1RT are also disclosed.
机译:无环核苷类似物,例如无环鸟苷,更昔洛韦,喷昔洛韦和相应的前药,即伐昔洛韦,缬更昔洛韦和泛昔洛韦,已分别鉴定为端粒酶(由TERT编码)和L-1编码的逆转录酶( LINE-1)RT,可用于治疗或预防由两种酶诱导或介导的癌症。在患者中治疗或预防此类癌症的方法包括在患者细胞中给予治疗有效量的具有逆转录酶抑制剂或拮抗剂的组合物。抑制剂或拮抗剂阻止端粒酶阳性和端粒酶阴性细胞中端粒的延长。还公开了用于检测表达TERT和L1RT的病理性增殖细胞的方法和试剂盒。

著录项

  • 公开/公告号US9078901B2

    专利类型

  • 公开/公告日2015-07-14

    原文格式PDF

  • 申请/专利权人 ALT SOLUTIONS INC.;

    申请/专利号US201314104752

  • 发明设计人 IGOR E. BONDAREV;

    申请日2013-12-12

  • 分类号A61K31/70;A01N43/04;A61K31/522;A61K45/06;A61N5/10;A61K9;

  • 国家 US

  • 入库时间 2022-08-21 15:21:41

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号